The company's lead compound, BGP-15, has been found effective in treating adverse metabolic conditions, including type 2 diabetes mellitus, by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation. N-Gene's pipeline of proprietary drugs aims to treat insulin-resistance syndrome, improve cancer chemotherapy, and slow skin aging, providing pharmaceutical businesses with a series of synthetic molecules to achieve these goals.